CANBRIDGE PHARM.DL-00001 (MF1) - Net Assets
Based on the latest financial reports, CANBRIDGE PHARM.DL-00001 (MF1) has net assets worth €-341.75 Million EUR (≈ $-399.55 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€165.39 Million ≈ $193.36 Million USD) and total liabilities (€507.15 Million ≈ $592.91 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read CANBRIDGE PHARM.DL-00001 total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-341.75 Million |
| % of Total Assets | -206.63% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 28.7 |
CANBRIDGE PHARM.DL-00001 - Net Assets Trend (2021–2025)
This chart illustrates how CANBRIDGE PHARM.DL-00001's net assets have evolved over time, based on quarterly financial data. Also explore CANBRIDGE PHARM.DL-00001 assets under control for the complete picture of this company's asset base.
Annual Net Assets for CANBRIDGE PHARM.DL-00001 (2021–2025)
The table below shows the annual net assets of CANBRIDGE PHARM.DL-00001 from 2021 to 2025. For live valuation and market cap data, see MF1 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €-341.75 Million ≈ $-399.55 Million |
+27.97% |
| 2024-12-31 | €-474.49 Million ≈ $-554.73 Million |
-1092.54% |
| 2023-12-31 | €-39.79 Million ≈ $-46.52 Million |
-112.89% |
| 2022-12-31 | €308.56 Million ≈ $360.73 Million |
-55.50% |
| 2021-12-31 | €693.39 Million ≈ $810.65 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CANBRIDGE PHARM.DL-00001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 126144900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €3.85 Billion | % |
| Total Equity | €-341.75 Million | 100.00% |
CANBRIDGE PHARM.DL-00001 Competitors by Market Cap
The table below lists competitors of CANBRIDGE PHARM.DL-00001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Logistic Properties of the Americas
NYSE MKT:LPA
|
$98.02 Million |
|
DATA MODUL Aktiengesellschaft Produktion und Vertrieb von elektronischen Systemen
XETRA:DAM
|
$98.03 Million |
|
Martin Midstream Partners LP
NASDAQ:MMLP
|
$98.03 Million |
|
PT DFI Retail Nusantara Tbk
JK:HERO
|
$98.06 Million |
|
Simpac
KO:009160
|
$97.99 Million |
|
Hexa Tradex Limited
NSE:HEXATRADEX
|
$97.99 Million |
|
Silla Co.Ltd
KO:004970
|
$97.99 Million |
|
Energy Transition Minerals Ltd
AU:ETM
|
$97.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CANBRIDGE PHARM.DL-00001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -474,488,000 to -341,755,000, a change of 132,733,000.
- Net income of 14,818,000 contributed positively to equity growth.
- New share issuances of 111,649,000 increased equity.
- Other factors increased equity by 6,266,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €14.82 Million | +4.34% |
| Share Issuances | €111.65 Million | +32.67% |
| Other Changes | €6.27 Million | +1.83% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares CANBRIDGE PHARM.DL-00001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €1.63 | €0.16 | x |
| 2022-12-31 | €0.73 | €0.16 | x |
| 2023-12-31 | €-0.09 | €0.16 | x |
| 2024-12-31 | €-1.12 | €0.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CANBRIDGE PHARM.DL-00001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 29.65%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-62.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -155.32% | -3456.26% | 0.03x | 1.29x | €-1.15 Billion |
| 2022 | -156.69% | -612.21% | 0.11x | 2.28x | €-514.33 Million |
| 2023 | 0.00% | -368.26% | 0.26x | 0.00x | €-374.86 Million |
| 2024 | 0.00% | -520.10% | 0.73x | 0.00x | €-395.17 Million |
| 2025 | 0.00% | 29.65% | 0.30x | 0.00x | €48.99 Million |
Industry Comparison
This section compares CANBRIDGE PHARM.DL-00001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,132,095,555
- Average return on equity (ROE) among peers: -68.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CANBRIDGE PHARM.DL-00001 (MF1) | €-341.75 Million | -155.32% | N/A | $98.00 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $242.58 Million | -85.63% | 0.52x | $204.16 Million |
| PreveCeutical Medical Inc (18H) | $-2.29 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.05 Billion | -15.51% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $1.82 Billion |
| BioNTech SE (22UA) | $19.22 Billion | -5.91% | 0.14x | $20.05 Billion |
About CANBRIDGE PHARM.DL-00001
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatme… Read more